HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
暂无分享,去创建一个
J. Barrett | M. Tremelling | M. Parkes | C. Lees | J. Mansfield | Fraser Cummings | C. Anderson | D. McGovern | C. Hawkey | C. Edwards | C. Mowat | L. Moutsianas | A. Hart | R. Russell | M. Reppell | N. Kennedy | D. Rice | G. Heap | A. Simmons | D. Gaya | S. Kirkham | E. Wesley | S. Bloom | A. Agrawal | S. Sebastian | J. Lindsay | C. Selinger | Tariq Ahmad | J. Limdi | J. Fell | T. Mcdonald | G. Chung‐Faye | P. Irving | Z. Mahmood | F. Torrente | J. de Caestecker | N. Trudgill | A. Dhar | T. Orchard | R. Pollok | T. Iqbal | P. Goggin | C. Nwokolo | S. Lal | J. Goodhand | J. Snook | J. Gordon | N. Croft | S. Levison | M. Brookes | D. Watts | S. Bouri | J. W. Hart | A. Beale | N. Chanchlani | A. Sazonovs | Stephen J. Lewis | P. Dunckley | C. Tzivinikos | B. Colleypriest | L. Grellier | Alka Thakur | A. Rodrigues | M. Perry | M. Harbord | S. Foley | A. De Silva | H. Jafferbhoy | S. Sonwalkar | R. Cooney | S. Cooper | N. Direkze | J. Mawdsley | S. Panter | K. Monahan | C. Charlton | S. Sen | D. Vani | Thankam Paul | B. Hope | V. Zamvar | R. Chaudhary | A. Shenoy | Matt W. Johnson | J. Cummings | R. Shenderey | D. Elphick | S. Langlands | D. Basude | Neeraj Prasad | A. Mcnair | D. Hobday | G. Macfaul | Anita Modi | T. Tham | J. Beckly | S. Weaver | S. Murugesan | S. Bridger | Richard Miller | S. Ramakrishnan | R. H. Phillips | S. Gore | R. Saich | S. Evans | C. Bewshea | G. Walker | V. Patel | Z. Mazhar | V. Kaushik | Salil Singh | C. Preston | Assad M. Butt | Melissa Smith | Juan De La Revella Negro | Chris Ewen MacDonald | A. Gunasekera | A. Cole | J. Doherty | S. de Silva | P. Mayhead | Gareth T. Jones | L. Gervais | Tariq Mahmood | P. Banim | Deb Ghosh | A. Azaz | L. Armstrong | Claire Bell | R. Hariraj | Helen Matthews | A. Willmott | P. Sathish Babu | Charles D Murray | Neil Shah | Kasamu Dawa Kabiru | B. Baburajan | Bim Bhaduri | Andrew Adebayo Fagbemi | G. Watts | A. Ramadas | M. Morris | M. Tighe | Mark S. Smith | Suranga Dharmisari | M. Carter | B. McLain | A. J. Pigott | R. Johnston | A. Bell | Andy Li | T. Mahmood | C. Murray | G. Chung-faye | Melissa A. Smith | B. Bhaduri | B. Mclain | G. Chung-Faye
[1] M. Parkes,et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.
[2] Jacob F. Degner,et al. Identification of HLA-DRB1 association to adalimumab immunogenicity , 2018, PloS one.
[3] S. Vermeire,et al. Immunogenicity of biologics in inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.
[4] M. García-Simón,et al. A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF , 2018, International journal of medical sciences.
[5] F. Carrat,et al. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease , 2017, JAMA.
[6] Gonçalo R. Abecasis,et al. GAS Power Calculator: web-based power calculator for genetic association studies , 2017, bioRxiv.
[7] David C. Wilson,et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease , 2016, Nature Genetics.
[8] T. Matsui,et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. , 2016, Journal of Crohn's & colitis.
[9] P. Camargos,et al. Do HLA class II genes protect against pulmonary tuberculosis? A systematic review and meta-analysis , 2016, European Journal of Clinical Microbiology & Infectious Diseases.
[10] S. Vermeire,et al. Immunogenicity to infliximab is associated with HLA-DRB1 , 2015, Gut.
[11] Tariq Ahmad,et al. Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature , 2015, Annals of clinical biochemistry.
[12] Hailiang Huang,et al. High density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis , 2014, Nature Genetics.
[13] Andrew R. Jones,et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..
[14] J. Lewis,et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. , 2014, Gastroenterology.
[15] P. Rutgeerts,et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.
[16] W. Sandborn,et al. Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry , 2014, The American Journal of Gastroenterology.
[17] M. Pirmohamed,et al. Challenges and approaches for the development of safer immunomodulatory biologics , 2013, Nature Reviews Drug Discovery.
[18] A. Pizzuti,et al. HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typing , 2012, Journal of Biomedical Science.
[19] Hariklia Eleftherohorinou,et al. Pathway-driven gene stability selection of two rheumatoid arthritis GWAS identifies and validates new susceptibility genes in receptor mediated signalling pathways. , 2011, Human molecular genetics.
[20] K. Mchugh,et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. , 2011, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[21] J. She,et al. Association between type 1 diabetes and GWAS SNPs in the southeast US Caucasian population , 2011, Genes and Immunity.
[22] B. Dijkmans,et al. IL10 GGC Haplotype Is Positively and HLA-DQA1*05-DQB1*02 Is Negatively Associated with Radiographic Progression in Undifferentiated Arthritis , 2010, The Journal of Rheumatology.
[23] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[24] S. Hanauer,et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.
[25] Simon C. Potter,et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.
[26] W. Martin,et al. De-immunization of therapeutic proteins by T-cell epitope modification. , 2005, Developments in biologicals.